CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 134 enrolled
Drug / intervention
Sertraline +1 moredrug
Likely dose
Sertraline 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00368550
NCT00368550Phase 4Completed
CompareCT.gov

Sertraline Pharmacotherapy for Alcoholism Subtypes

UConn Health·interventional·Posted Aug 24, 2006·Updated Jun 21, 2011

In Brief

A Phase 4 clinical trial evaluating Sertraline and Placebo for Alcoholism. Completed, enrolled 134 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether Sertraline, compared to placebo, is effective in the treatment of alcohol dependence as a function of the subtype of alcoholic patient being treated. This involved administering sertraline (to a maximum of 200 mg/day) or an inactive placebo for a 14-week treatment period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 24, 2006
Enrollment StartFeb 1, 2004
Primary CompletionJun 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 19.9 years ago

Interventions

Sertralinedrug

Sertraline (to a maximum of 200 mg/day) for 14-week treatment period

Placebodrug

Placebo for 14-week treatment period